Compare GPRE & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | IMTX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 992.8M |
| IPO Year | 2004 | 2020 |
| Metric | GPRE | IMTX |
|---|---|---|
| Price | $11.65 | $5.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $18.67 | $16.03 |
| AVG Volume (30 Days) | ★ 1.0M | 976.6K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.15 | N/A |
| P/E Ratio | $5.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.31 | $5.95 |
| 52 Week High | $19.65 | $12.41 |
| Indicator | GPRE | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 30.64 |
| Support Level | N/A | N/A |
| Resistance Level | $15.79 | $11.82 |
| Average True Range (ATR) | 0.62 | 0.46 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 5.48 | 0.89 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.